Veranex
Veranex is a privately held, Raleigh-headquartered Innovation CRO providing integrated design, preclinical, clinical, regulatory, quality, and commercialization services to medical device and IVD developers worldwide, supported by Summit Partners and operating 15 international hubs with 800+ cross-disciplinary experts serving 700+ clients.
- Company typePrivate
- Founded2021
- HeadquartersRaleigh, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Veranex does
Veranex is a privately held, Raleigh-headquartered medical technology services platform founded in 2021 that operates the industry's first integrated Innovation CRO (iCRO), unifying product design, preclinical research, clinical research, regulatory consulting, quality consulting, and commercialization under a single engagement model. The platform is composed of acquired entities including Ximedica, Quartesian, Boston Healthcare Associates, Experien Group, IMMR, Worrell, Medidee, Fusion Biotec, T3 Labs, and HORUS Scientific, with sub-brand Veranex Biopharma extending into biopharma clinical trials. Underlying technical capabilities include GLP and non-GLP preclinical studies, advanced cardiovascular surgical models (including TAVR landing zone development) performed at purpose-built facilities in Atlanta (33,000 sq ft) and Paris, integrated histopathology, Aquilion Prime SP and GE LightSpeed VCT 64-slice imaging, ISO 13485-certified quality management, and dedicated regulatory practices for FDA, EU MDR, IVDR, and EU Authorized Representative services across cardiovascular, IVD, neurology, ophthalmology, and regenerative medicine therapeutic areas.
The company is backed primarily by Summit Partners, with additional strategic capital from Accelmed Partners II and Lauxera Capital Partners. Veranex sells professional services through direct enterprise sales and website-based project requests to medical device and IVD developers ranging from startups to large established manufacturers, and also serves CROs and life sciences companies with SAS programming and clinical data management services. Pricing is custom and quote-based on a multi-year contract cadence, consistent with B2B professional services. The company operates approximately 15 international hubs across the U.S., U.K., France, Switzerland, Germany, Sweden, Ukraine, and India, employing an 800+ cross-disciplinary expert bench that has supported 700+ clients and 1,000+ programs.
Revenue is not publicly disclosed and the company remains in active growth mode, with no identified IPO or secondary market transaction. Recent operating actions include the November 2025 appointment of a former U.S. FDA physician as Chief Medical Officer and ongoing platform consolidation through targeted acquisitions. Competitive positioning rests on offering a single accountable partner across the entire medtech development lifecycle, thereby reducing vendor hand-offs, redundant testing, and regulatory friction for clients.
Veranex firmographics
Firmographics- Name
- Veranex
- Legal name
- Veranex
- Website
- https://veranex.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Veranex is a privately held, Raleigh-headquartered Innovation CRO providing integrated design, preclinical, clinical, regulatory, quality, and commercialization services to medical device and IVD developers worldwide, supported by Summit Partners and operating 15 international hubs with 800+ cross-disciplinary experts serving 700+ clients.
- Ownership category
- akta.pro rank
Veranex industry classification
Industry- Product category
- Medical Device Contract Research Organization Services
- NAICS
- Scientific Research and Development Services (5417), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Services-Testing Laboratories (8734)
- akta.pro primary industry
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
- akta.pro secondary industries
- Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)
Keywords
Where Veranex is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices12 records
Markets served
Veranex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Medical Device Development Services: Comprehensive professional services for medical device and IVD development including design, engineering, regulatory consulting, quality management, preclinical studies, clinical research, and commercialization support. Revenue is generated through project-based consulting fees and service contracts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Project-Based Engagement |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Veranex product offering
Product offeringCore offering
Veranex is an integrated Innovation CRO (iCRO) that delivers concept-through-commercialization services for medical device and in-vitro diagnostic (IVD) companies. Its offering unifies product design and engineering, GLP/non-GLP preclinical and pathology studies, clinical trial execution, regulatory and quality consulting, and market access and commercialization support under a single contract.
Product overview
Veranex is an Innovation CRO (Contract Research Organization) offering an integrated medtech product development platform that unifies design, preclinical, clinical, regulatory, quality, and commercialization services under one roof. The platform consists of core service lines including Design & Development Services, Preclinical & Pathology Services, Clinical Research (CRO) Services, Regulatory Consulting Services, Quality Consulting Services, and Commercialization Services. These are complemented by specialized solutions such as Biocompatibility, Digital Health, Medical Device Consulting, Technical Writing, Testing Solutions, and Training Curriculum. The company also maintains therapeutic area expertise in Cardiovascular, In-vitro Diagnostics, Neurology, and Ophthalmology. A sub-brand, Veranex Biopharma, extends services to biopharma clinical trials. Veranex operates through 15 international hubs across the U.S., Europe, and India, with approximately 800 cross-disciplinary experts supporting over 1,000 programs accelerated and 700 global clients.
Differentiator
Problem solved
Functional benefit
Brands
- Veranex Biopharma: Next-generation biopharma solutions and clinical trials support service offering.
Products and services
- Design & Development Services
Quantifiable outcome
- 1000+ programs accelerated across design to commercialization
- +4 more outcomes
Companies that use Veranex
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Veranex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Veranex partnerships and signals
Strategic signalScale indicators8 records
Recent moves7 records
Expansion highlights6 records
Veranex competitors and assessment
Company assessmentDirect peers
- NAMSA: NAMSA is the longest-standing medtech-focused CRO offering preclinical, clinical, regulatory, and quality services across the full device and IVD lifecycle. It is the closest direct competitor to Veranex's iCRO model, with comparable therapeutic-area breadth and a similar integrated-service value proposition.
- Qserve Group: Qserve is a medtech-focused regulatory, clinical, and quality consultancy with deep EU MDR/IVDR expertise. It directly overlaps with Veranex's regulatory and quality consulting practice and is a frequent substitute for European medtech clients.
Broad incumbents
- WuXi AppTec: WuXi AppTec is a global CRO/CDMO providing preclinical, clinical, regulatory, and testing services across pharma, biotech, and medical devices. It is a broader incumbent with overlapping preclinical and regulatory capabilities that competes for medtech-services contracts at global scale.
- Charles River Laboratories: Charles River is a large CRO/CDMO with a leading preclinical and discovery-services platform that competes with Veranex's GLP preclinical and surgical-model offerings. It brings substantially greater scale and a broader pharma/biotech customer base.
- IQVIA: IQVIA is the largest global CRO with deep clinical operations, real-world evidence, and technology platforms. It competes for enterprise medtech CRO engagements where scale, data infrastructure, and geographic reach matter most.
- ICON plc: ICON is a top-three global CRO with significant medtech and IVD clinical research capability following its PRA Health Sciences combination. It competes directly with Veranex's clinical research services for larger device sponsors.
- Medpace: Medpace is a mid-to-large CRO with strong full-service clinical operations across multiple therapeutic areas including medical devices. Its operating model and reputation for execution are benchmarks Veranex is measured against.
- Fortrea: Fortrea is the post-spin clinical development services business of Labcorp, providing CRO services with overlap to Veranex's clinical research and biostatistics/data-management offerings. It is a scaled alternative for enterprise medtech sponsors.
- Eurofins Scientific: Eurofins is a global testing-services platform with substantial medical-device testing and IVD laboratory capabilities. It competes with Veranex's biocompatibility, testing, and IVD validation services and offers broader geographic lab coverage.
- TÜV SÜD: TÜV SÜD is a global testing, inspection, certification, and Notified Body organization with deep medtech regulatory and quality expertise. It is a key alternative for device makers seeking EU MDR/IVDR Notified Body and quality system support that Veranex also provides.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Veranex social profiles
Digital presenceVeranex compliance and trust
Trust signalCompliance1 record
Veranex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Veranex leadership team
Management profileNumber of profiles
Profiles16 records
Veranex subsidiaries and ownership
Company hierarchySubsidiaries10 records
Veranex funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Veranex M&A and investment
M&A and investmentM&A15 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Veranex
What does Veranex do?
Veranex is an integrated Innovation CRO (iCRO) that delivers concept-through-commercialization services for medical device and in-vitro diagnostic (IVD) companies. Its offering unifies product design and engineering, GLP/non-GLP preclinical and pathology studies, clinical trial execution, regulatory and quality consulting, and market access and commercialization support under a single contract.
Is Veranex a public or private company?
Veranex is a private company. It is classified as private equity controlled and is currently operating.
When was Veranex founded?
Veranex was founded in 2021. It employs 1,001 to 5,000 people.
Where is Veranex based?
Veranex is headquartered in Raleigh, United States, in the North America region.
How does Veranex make money?
One revenue line is on record: medical Device Development Services.
Who are Veranex's main competitors?
Direct peers on record are NAMSA and Qserve Group. Broad incumbents are WuXi AppTec, Charles River Laboratories, IQVIA, ICON plc, Medpace, Fortrea, Eurofins Scientific and TÜV SÜD.
Does Veranex have an API?
No public API is recorded for Veranex.
What industry is Veranex in?
Veranex's product category is Medical Device Contract Research Organization Services. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 5417 and its SIC code is 8734.